Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free STAB Stock Alerts

Statera Biopharma (STAB) Competitors

Statera Biopharma logo
$0.0001 0.00 (0.00%)
As of 07/24/2026 01:41 PM Eastern
Compare

STAB vs. CMRA, ADTX, EFTR, EVLO, and SMFL

Should you buy Statera Biopharma stock or one of its competitors? MarketBeat compares Statera Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Statera Biopharma include Comera Life Sciences (CMRA), Aditxt (ADTX), eFFECTOR Therapeutics (EFTR), Evelo Biosciences (EVLO), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.

How does Statera Biopharma compare to Comera Life Sciences?

Statera Biopharma (NASDAQ:STAB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Comera Life Sciences Neutral

Statera Biopharma has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Statera Biopharma has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Statera Biopharma has lower revenue, but higher earnings than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.20-$41.71M-$100.79 thousandN/A
Statera BiopharmaN/AN/AN/AN/AN/A

Aditxt has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Statera Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Aditxt Neutral
Statera Biopharma Neutral

Statera Biopharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Statera Biopharma's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Statera Biopharma N/A N/A N/A

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aditxt beats Statera Biopharma on 5 of the 9 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Statera Biopharma Neutral

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Statera BiopharmaN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Statera Biopharma N/A N/A N/A

eFFECTOR Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Evelo Biosciences?

Statera Biopharma (NASDAQ:STAB) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Statera Biopharma has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Evelo Biosciences Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Evelo Biosciences N/A N/A N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Evelo Biosciences beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Smart for Life?

Statera Biopharma (NASDAQ:STAB) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

28.4% of Smart for Life shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Smart for Life N/A N/A N/A

Statera Biopharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Statera Biopharma has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.05, suggesting that its stock price is 1,405% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Smart for Life Neutral

Summary

Smart for Life beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STAB vs. The Competition

Export
MetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$975.11M$6.87B$12.26B
Dividend YieldN/A4.84%2.67%9.79%
P/E Ratio0.001.5327.1423.64
Price / SalesN/A105.75517.0688.99
Price / CashN/A20.0650.5459.64
Price / BookN/A8.4710.286.07
Net IncomeN/A-$2.70M$3.60B$331.99M
7 Day PerformanceN/A-2.29%-1.27%-0.63%
1 Month PerformanceN/A-3.97%-0.37%-2.00%
1 Year PerformanceN/A27.39%18.30%13.62%

Statera Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
N/A$0.00
flat		N/A+0.0%$1KN/AN/A20
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ADTX
Aditxt
0.1514 of 5 stars		$0.00
+20.0%		N/A-100.0%$2K$14.34KN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
-16.7%		N/A+300.0%$2KN/AN/A10
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel